Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation
The aim of review. To analyze and present data of the foreign pharmacogenetic studies devoted to improvement of pharmacological therapy of colorectal cancer (CRC), in particular those, focused on the drugs with general cytostatic action: 5-fluorouracil derivatives, irinotecan and platinum agents.Sum...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2015-12-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860146277711872 |
|---|---|
| author | N. B. Zakharzhevskaya N. A. Kulemin Ye. A. Babikova Ye. B. Khomyakova E. V. Generozov |
| author_facet | N. B. Zakharzhevskaya N. A. Kulemin Ye. A. Babikova Ye. B. Khomyakova E. V. Generozov |
| author_sort | N. B. Zakharzhevskaya |
| collection | DOAJ |
| description | The aim of review. To analyze and present data of the foreign pharmacogenetic studies devoted to improvement of pharmacological therapy of colorectal cancer (CRC), in particular those, focused on the drugs with general cytostatic action: 5-fluorouracil derivatives, irinotecan and platinum agents.Summary. In the oncological diseases frequency spectrum CRC traditionally occupies the leading positions all over the world. The success of CRC chemotherapy depends significantly on the individual genetic features of the patient influencing both efficacy of pharmacological effects, and degree of side effects severity. If efficacy and necessity of pharmacogenetic investigation for such drugs of targeted therapy, as cetuximab, is already proven for the present time, it is still underestimated for the widely applied drugs of general cytostatic action. This review presents systematic and generalized data on the most informative genetic markers which analysis can be used for optimization of treatment of CRC patients at multicomponent modes of chemotherapy, such as FOLFIRI and FOLFOX. |
| format | Article |
| id | doaj-art-9c5d0ff372d14723a1cda2f63e3dd94e |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2015-12-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-9c5d0ff372d14723a1cda2f63e3dd94e2025-02-10T16:14:34ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732015-12-012566776647Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimationN. B. Zakharzhevskaya0N. A. Kulemin1Ye. A. Babikova2Ye. B. Khomyakova3E. V. Generozov4Federal research and clinical center of physical-chemical medicine, Federal medical biological agencyFederal research and clinical center of physical-chemical medicine, Federal medical biological agencyFederal research and clinical center of physical-chemical medicine, Federal medical biological agencyFederal research and clinical center of physical-chemical medicine, Federal medical biological agencyFederal research and clinical center of physical-chemical medicine, Federal medical biological agencyThe aim of review. To analyze and present data of the foreign pharmacogenetic studies devoted to improvement of pharmacological therapy of colorectal cancer (CRC), in particular those, focused on the drugs with general cytostatic action: 5-fluorouracil derivatives, irinotecan and platinum agents.Summary. In the oncological diseases frequency spectrum CRC traditionally occupies the leading positions all over the world. The success of CRC chemotherapy depends significantly on the individual genetic features of the patient influencing both efficacy of pharmacological effects, and degree of side effects severity. If efficacy and necessity of pharmacogenetic investigation for such drugs of targeted therapy, as cetuximab, is already proven for the present time, it is still underestimated for the widely applied drugs of general cytostatic action. This review presents systematic and generalized data on the most informative genetic markers which analysis can be used for optimization of treatment of CRC patients at multicomponent modes of chemotherapy, such as FOLFIRI and FOLFOX.https://www.gastro-j.ru/jour/article/view/1040pharmacogenetic markerscolorectal cancerefficacy of antineoplastic treatmentgenetic analysis |
| spellingShingle | N. B. Zakharzhevskaya N. A. Kulemin Ye. A. Babikova Ye. B. Khomyakova E. V. Generozov Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation Российский журнал гастроэнтерологии, гепатологии, колопроктологии pharmacogenetic markers colorectal cancer efficacy of antineoplastic treatment genetic analysis |
| title | Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation |
| title_full | Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation |
| title_fullStr | Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation |
| title_full_unstemmed | Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation |
| title_short | Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation |
| title_sort | pharmacogenetic markers of colorectal cancer treatment new approaches for cytostatic drugs efficacy estimation |
| topic | pharmacogenetic markers colorectal cancer efficacy of antineoplastic treatment genetic analysis |
| url | https://www.gastro-j.ru/jour/article/view/1040 |
| work_keys_str_mv | AT nbzakharzhevskaya pharmacogeneticmarkersofcolorectalcancertreatmentnewapproachesforcytostaticdrugsefficacyestimation AT nakulemin pharmacogeneticmarkersofcolorectalcancertreatmentnewapproachesforcytostaticdrugsefficacyestimation AT yeababikova pharmacogeneticmarkersofcolorectalcancertreatmentnewapproachesforcytostaticdrugsefficacyestimation AT yebkhomyakova pharmacogeneticmarkersofcolorectalcancertreatmentnewapproachesforcytostaticdrugsefficacyestimation AT evgenerozov pharmacogeneticmarkersofcolorectalcancertreatmentnewapproachesforcytostaticdrugsefficacyestimation |